Related Experiment Video
Updated: Sep 28, 2025
In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model
Published on: October 3, 2011
A Review on the Design, Synthesis, and Structure-activity Relationships of Benzothiazole Derivatives against Hypoxic
Akif Hakan Kurt1, Lokman Ayaz2, Furkan Ayaz3
1Department of Medicinal Pharmacology, Faculty of Medicine, Bolu Abant İzzet Baysal University, 14030, Bolu, Turkey.
Abstract:
There has been a growing body of studies on benzothiazoles and benzothiazole derivatives as strong and effective anti-tumor agents against lung, liver, pancreas, breast, and brain tumors. Due to the highly proliferative nature of the tumor cells, the oxygen levels get lower than that of normal tissues in the tumor microenvironment. This situation is called hypoxia and has been associated with increased ability for carcinogenesis. For the drug design and development strategies, the hypoxic nature of the tumor tissues has been exploited more aggressively. Hypoxia itself acts as a signal initiating system to activate the pathways that eventually lead to the spread of the tumor cells into the different tissues, increases the rate of DNA damage, and eventually ends up with more mutation levels that may increase the drug resistance. As one of the major mediators of hypoxic response, hypoxia-inducible factors (HIFs) have been shown to activate angiogenesis, metastasis, apoptosis resistance, and many other protumorigenic responses in cancer development. In the current review, we will be discussing the design, synthesis, and structureactivity relationships of benzothiazole derivatives against hypoxic tumors such as lung, liver, pancreas, breast, and brain as potential anti-cancer drug candidates. The focus points of the study will be the biology behind carcinogenesis and how hypoxia contributes to the process, recent studies on benzothiazole and its derivatives as anti-cancer agents against hypoxic cancers, conclusions, and future perspectives. We believe that this review will be useful for researchers in the field of drug design during their studies to generate novel benzothiazole-containing hybrids against hypoxic tumors with higher efficacies.
Insights
Benzothiazole derivatives show promise as anti-cancer drugs targeting hypoxic tumors. This review explores their design and effectiveness against lung, liver, pancreas, breast, and brain cancers, offering insights for drug development.
Area of Science:
- Medicinal Chemistry
- Oncology
- Cancer Biology
Background:
- Tumor hypoxia, a common characteristic of solid tumors, promotes carcinogenesis, metastasis, and drug resistance.
- Hypoxia-inducible factors (HIFs) are key mediators of the hypoxic response, driving protumorigenic processes like angiogenesis and apoptosis resistance.
- Benzothiazole derivatives have emerged as a significant class of compounds with potent anti-tumor activity against various cancer types.
Purpose of the Study:
- To review the design, synthesis, and structure-activity relationships of benzothiazole derivatives as anti-cancer agents.
- To highlight the potential of these compounds against hypoxic tumors, including lung, liver, pancreas, breast, and brain cancers.
- To provide insights into the biological mechanisms of carcinogenesis influenced by hypoxia.
Main Methods:
- Literature review of recent studies on benzothiazole derivatives and their anti-cancer properties.
- Analysis of structure-activity relationships (SAR) of benzothiazole compounds in the context of hypoxic tumors.
- Discussion of the role of hypoxia and HIFs in cancer development and progression.
Main Results:
- Benzothiazole derivatives demonstrate significant efficacy against a range of hypoxic tumors.
- Specific structural modifications of benzothiazoles can enhance their anti-cancer activity and target hypoxic environments.
- The review consolidates current knowledge on benzothiazole-based therapeutics for hypoxic cancers.
Conclusions:
- Benzothiazole derivatives represent a promising scaffold for the development of novel anti-cancer drugs targeting hypoxic tumors.
- Further research into SAR and drug delivery mechanisms can optimize the efficacy of these agents.
- This review serves as a valuable resource for researchers aiming to design next-generation therapeutics for hypoxic cancers.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...